HAGAR GWave Awarded FDA Breakthrough Device Designation
Expediting Development of GWave technology that may potentially improve the health and quality of life for millions of diabetes patients
TEL AVIV, Israel--(BUSINESS WIRE)-- The US Food and Drug Administration (FDA) granted Breakthrough Device Designation for Hagar’s GWave, the world's first non-invasive continuous glucose monitoring technology that uses radiofrequency (RF) waves to measure glucose levels in the blood.
Today’s announcement that GWave received Breakthrough Device Designation from the FDA follows the $11.7 million Series B funding round earlier this year led by a returning investor, Columbia Pacific, that saw HAGAR’s total funds raised increase to $17.1 million. Since its inception, the Breakthrough Device Designation has opened the door to diabetes device innovation and has sped up the development and assessment of such devices that promise more effective and safe treatments or diagnoses for this life-threatening or irreversibly debilitating condition.
GWave First Generation is a third of the size of a smartphone and involves less RF exposure than a smartphone. The device measures blood glucose levels without requiring blood from pricking the skin. Measuring blood glucose frequently is essential for people with diabetes on insulin treatment and helpful for most other people with diabetes and prediabetes. Moreover, this easy, painless to use device can enable early detection of glucose elevations and encouragement of good dietary and exercise practices. Earlier application of these lifestyle changes can help to prevent development of type 2 diabetes, the much more common form of diabetes.
“The GWave technology is impressive. I believe it has the potential to significantly improve the management of diabetes,” said Roy Beck, MD PhD, a physician and epidemiologist who is the Medical Director of the JAEB Center for Health Research in Tampa, FL. Dr. Beck has more than 25 years of experience directing and coordinating multi-center clinical trials, with type 1 diabetes being a major focus of his research.
In a completed pilot study, blood glucose levels assessed by GWave were compared to measurements performed by a hexokinase core laboratory assay during an oral glucose tolerance test (OGTT) and found to be accurate in detecting real-time blood glucose. Additional studies are scheduled to be published in coming months.
“Receiving FDA Breakthrough Designation reflects our commitment to deliver innovative technology targeting one of the world’s most significant chronic diseases, one which affects more than 422 million people, 8.5% of the world’s population. Our mission at HAGAR is to materially improve the health and quality of life of people impacted by diabetes,” said Dr. Gerry Waintraub, CTO and co-founder of HAGAR.
Receipt of this designation coincides with HAGAR’s preparation to commence a study before the end of the year at the Schneider Children’s Medical Center in Israel on adults with diabetes.
“The study will involve 250 patients with type 1 and type 2 diabetes and will test the accuracy of GWave on a diverse group of individuals across a range of demographic criteria. We also have a second study due to start this winter, which will test the device’s accuracy during conditions of rapidly changing glucose levels,” said Dr. Irl Hirsch, Medical Advisor to HAGAR and Professor of Medicine and the Diabetes Treatment and Teaching Chair in the Division of Metabolism, Endocrinology, and Nutrition at the University of Washington.
HAGAR is also developing a second-generation sensor device that can easily be integrated into common smartwatches currently available on the market.
The article is available for review on the journal’s website here.
About HAGAR N.I.G.
HAGAR N.I.G. (Noninvasive Glucose monitoring) is the developer of GWave, the world's first non-invasive continuous glucose monitoring technology that uses RF waves to measure glucose levels in the blood continuously. GWave First Generation is a third of the size of a smartphone, and GWave Second Generation, currently in development, will be a sensor built into a comfortable watch the size of a smartwatch that sends glucose readings to the user via a smartphone app that can easily be shared with a healthcare provider.
For more information, visit: https://www.hagartech.com/
Source: HAGAR N.I.G.